<DOC>
	<DOCNO>NCT02040116</DOCNO>
	<brief_summary>The purpose study evaluate impact rapid infusion rituximab incidence infusion-related reaction patient Autoimmune Diseases .</brief_summary>
	<brief_title>Study Evaluating Rapid Infusion Rituximab Patients With Autoimmune Diseases</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Autoimmune patient Wake Forest Baptist Health eligible rituximab therapy Tolerate standard infusion rituximab ≤ grade 2 hypersensitivity reaction Consent participate rapid infusion study Age ≥ 18 year ≤ 80 year Tolerate standard infusion rituximab ≥ grade 3 hypersensitivity reaction Neurocognitive impairment ( i.e . dementia , Alzheimers , et al )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Rapid Infusion Rituximab</keyword>
</DOC>